Ace the 2025 RAC Exam – Unleash Your Regulatory Expertise Today!

Question: 1 / 400

How does the regulatory pathway for orphan drugs differ?

There are no regulations for orphan drugs

Orphan drugs have a distinct approval process with development incentives

The regulatory pathway for orphan drugs is distinct primarily because these drugs are developed to treat rare diseases and conditions, which affect a limited percentage of the population. Due to the challenges associated with commercial viability in these cases, regulatory agencies have established specific incentives to encourage the development of orphan drugs. These incentives can include tax credits for clinical research, assistance in the drug development process, and an extended period of market exclusivity upon approval.

The existence of a unique approval process means that orphan drugs benefit from a regulatory environment designed to facilitate their development and availability to patients in need. This process aims to mitigate the economic hurdles faced by manufacturers when investing in treatments for conditions that might not be profitable in a traditional market scenario.

Get further explanation with Examzify DeepDiveBeta

Orphan drugs are banned from marketing

Orphan drugs follow the same process as regular drugs without incentives

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy